SCHEMBL19436610

SCHEMBL19436610

O=C1NC2=CN=CNC2=Nc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.37
CASP3 P42574 2/20 0.37
CASP7 P55210 2/20 0.37
CASP6 P55212 2/20 0.37
CASP8 Q14790 2/20 0.37
CASP2 P42575 1/20 0.37
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
CYP1A2 P05177 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
CHEK2 O96017 1/20 0.33
LCK P06239 1/20 0.33
CDK2 P24941 1/20 0.33
MAPK8 P45983 1/20 0.33
CSNK1D P48730 1/20 0.33
GSK3A P49840 1/20 0.33
BLK P51451 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11281478 0.70 MAPT (0.42) GSK3BCASP3LMNAGAAMAPT
SCHEMBL4264647 0.67 DRD2 (0.36)
SCHEMBL21296775 0.62 GSK3B (0.52) GSK3BCASP3CASP7CASP6CASP8
SCHEMBL555451 0.62 GSK3B (0.52) GSK3BCASP3CASP7CASP6CASP8
SCHEMBL7980321 0.59 MAPT (0.56) GSK3BCASP3CASP7CASP6CASP8
SCHEMBL3541281 0.59 GSK3B (0.48) GSK3BCASP3CASP7CASP6CASP8
Phthalimide SCHEMBL11040503 0.58 GSK3B (1.00) GSK3BCASP3CASP7CASP6CASP8
Phthalimide SCHEMBL29366030 0.58 GSK3B (1.00) GSK3BCASP3CASP7CASP6CASP8
Phthalimide SCHEMBL64 0.58 GSK3B (1.00) GSK3BCASP3CASP7CASP6CASP8
Phthalimide SCHEMBL30125197 0.58 GSK3B (1.00) GSK3BCASP3CASP7CASP6CASP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3440084-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS Dana-Farber Cancer Institute, Inc. (US) 2019-02-13 EP disclosed
WO-2017177092-A1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING PI3K-MEDIATED DISORDERS DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-10-12 WO disclosed